108260-04-4

Upstream product

• 31461-05-9 (6R)-3-methyl-8-oxo-7t-(trimethylsilanyl-amino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid trimethylsilanyl ester 
• 33125-05-2 Boc-D-Phg-OH 
• 57872-59-0 (R)-2-(tert-butoxycarbonylamino)-2-(cyclohexa-1,4-dienyl)acetic acid 
• 24461-61-8 (R)-Phenylglycine methyl ester 
• 15690-38-7 (6R,7R)-7-amino-3-hydroxymethyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 34959-72-3 (6R,7R,4'R)-7-(2',2'-dimethyl-3'-nitroso-5'-oxo-4'-phenylimidazolidin-1'-yl)-3-methylceph-3-em-4-carboxylate 
• 22252-43-3 3-deacetyloxy-7-aminocephalosporanic acid 
• 2835-06-5 phenylglycin 
• 109429-60-9 (6R,7R,4'S)-7-(2',2'-dimethyl-3'-nitroso-5'-oxo-4'-phenylimidazolidin-1'-yl)-3-methylceph-3-em-4-carboxylate 
• 39879-59-9 2,2,2-trichloroethyl (1S,3S,5R,6R)-6-phenylacetamido-2,2-dimethylpenam-3-carboxylate, 1-oxide 
• 51795-31-4 (6R,7R)-7-amino-3-methylenecepham-4-carboxylic acid 
• 72059-35-9 7-aminodesacetoxy-cephalosporanic acid 
• 39754-01-3 cephalexin p-nitrobenzyl ester tosylate salt 
• 611-71-2 MANDELIC ACID 

Downstream Products

• 131602-28-3 7-<2-(Dihydro-5-methyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-29-4 7-<2-(Dihydro-5-ethyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-30-7 7-<2-(Dihydro-5-n-propyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-33-0 7-<2-(Dihydro-5-isopropyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131622-63-4 7-<2-(Dihydro-5-isobutyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-31-8 7-<2-(Dihydro-5-n-butyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-34-1 7-<2-(Dihydro-5-isopentyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-32-9 7-<2-(Dihydro-5-n-pentyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-36-3 7-<2-(Dihydro-5-benzyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-35-2 7-<2-(Dihydro-5-(2-furylmethyl)-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 131602-37-4 7-<2-(Dihydro-5-β-phenethyl-6-thioxo-2H-1,3,5-thiadiazine-3<4H>-yl)-2-phenyl>acetamido-3-methyl-3-cephem-4-carboxylic acid 
• 59310-01-9 (6R)-7t-((R)-2-formylamino-2-phenyl-acetylamino)-3-methyl-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 34959-72-3 (6R,7R,4'R)-7-(2',2'-dimethyl-3'-nitroso-5'-oxo-4'-phenylimidazolidin-1'-yl)-3-methylceph-3-em-4-carboxylate 
• 67341-53-1 2-hydroxy-3-phenyl-6-methylpyrazine 

Related news

A new biocompatible gentle aqueous biphasic system in cefalexin (cas 108260-04-4) partitioning containing nonionic Tween 20 surfactant and three organic/inorganic different salts09/01/2019

In this work, nonionic biocompatible Tween 20 based aqueous two-phase systems (ATPSs) were studied. These systems provide a gentle media with low interfacial tension for extraction of biomolecules. In accordance with the results, the top phase tends to be surfactant-rich and the bottom phase ten...detailed

The long-term impact of cefalexin (cas 108260-04-4) on organic substrate degradation and microbial community structure in EGSB system08/31/2019

In order to investigate long-term effect of cefalexin (CFX) on the performance of expanded granular sludge bed (EGSB) system and microbial community structure, two 1.47 L EGSB reactors E1 and E2 were designed and run for 224 days treating with synthetic antibiotic wastewater. For the purpose of ...detailed

Biodegradability enhancement of wastewater containing cefalexin (cas 108260-04-4) by means of the electro-Fenton oxidation process08/29/2019

The comparative degradation behavior of cefalexin (CLX) using advanced oxidation processes (AOPs) with the aim of improving CLX biodegradability was studied. Among the AOPs used, RuO2/Ti anodic oxidation (AO), AO in the presence of electro-generated H2O2 (AO-H2O2), and the electro-Fenton (EF) pr...detailed

Effect of surface properties of activated carbon fiber cathode on mineralization of antibiotic cefalexin (cas 108260-04-4) by electro-Fenton and photoelectro-Fenton treatments: Mineralization, kinetics and oxidation products08/28/2019

Solutions of 200 mg L−1 cefalexin (CLX), an antibiotic with high usage frequency and biodegradation resistance, have been comparatively degraded by electro-Fenton (EF) and photoelectro-Fenton (PEF) processes using two kinds of activated carbon fiber (ACF) cathodes with different physical propert...detailed

Inclusion of cefalexin (cas 108260-04-4) in SBA-15 mesoporus material and release property08/27/2019

SBA-15 (Santa Barbara Amorphous-15) is a high ordered mesoporous material. It has the advantages of a non-toxic property, good hydrothermal stability and thermal stability, etc. Inside inner surface a lot of silanols exist. Pore diameter size is uniform and pore size distribution is narrow. This...detailed

Susceptibility of coagulase-negative staphylococci to a kanamycin and cefalexin (cas 108260-04-4) combination08/26/2019

A combination of kanamycin and cefalexin was licensed in Europe in 2008 to treat bovine clinical mastitis. Preliminary broth and disk clinical breakpoints for this antibiotic combination have been proposed for Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, and Escherich...detailed

Oxidation of cefalexin (cas 108260-04-4) by thermally activated persulfate: Kinetics, products, and antibacterial activity change08/25/2019

While the widely used β-lactam antibiotics, such as cephalosporins, are known to be susceptible to oxidation by sulfate radical (SO4−), comprehensive study about SO4−-induced oxidation of cephalosporins is still limited, such as the impact of water matrices, and the structure and antibacterial ...detailed

Characterization of cefalexin (cas 108260-04-4) degradation capabilities of two Pseudomonas strains isolated from activated sludge08/24/2019

Pharmaceuticals have recently been regarded as contaminants of emerging concern. To date, there is limited knowledge about antibiotic-degrading microorganisms in conventional activated sludge treatment systems and their characteristics toward antibiotic degradation especially in the presence of ...detailed

Hydrophilic-interaction planar chromatography in ultra-sensitive determination of α-aminocephalosporin antibiotics. Application to analysis of cefalexin (cas 108260-04-4) in goat milk samples using modified QuEChERS extraction technique08/23/2019

A highly sensitive, selective and precise HPTLC method coupled with fluorescence detection was developed and validated for the determination of α-aminocephalosporin antibiotics; namely cefalexin, cefadroxil and cefradine in their standard solutions. The applicability of the developed methodolog...detailed

Relevant academic research and scientific papers

Preparation method of cefalexin

The invention belongs to the field of medicine synthesis, in particular to an improved method of a beta-lactam antibiotic cefalexin synthesis process. According to the method, 7-ADCA is used as a rawmaterial and is protected by carboxyl silane; after activation with alpha-aminophenylacetic acid hydrochloride and trifluoroacetic acid succinimide, condensation reaction is carried out; cefalexin isobtained through hydrolysis after-treatment, the proper pH value is controlled through hydrochloric acid after organic solvent and alkali adjustment treatment, and cefalexin crystals with extremely high purity are obtained. The method has the advantages of being easy and convenient to operate, mild in reaction condition, not prone to causing side reaction and capable of effectively removing impurities and preparing high-purity cefalexin.

PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS

The present invention relates to a composition comprising ≥85 wt% of an N-deacylated cephalosporin, a process for making the same and the use of said N-deacylated cephalosporin in the preparation of highly pure semi synthetic cephalosporins.

MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION

The present invention relates to a novel technology for forming fine particles with a size of 0.02?3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

Amino ester hydrolase from Xanthomonas campestris pv. campestris, ATCC 33913 for enzymatic synthesis of ampicillin

α-Amino ester hydrolases (AEH) are a small class of proteins, which are highly specific for hydrolysis or synthesis of α-amino containing amides and esters including β-lactam antibiotics such as ampicillin, amoxicillin, and cephalexin. A BLAST search revealed the sequence of a putative glutaryl 7-aminocephalosporanic acid (GL-7-ACA) acylase 93% identical to a known AEH from Xanthomonas citri. The gene, termed gaa, was cloned from the genomic DNA of Xanthomonas campestris pv. campestris sp. strain ATCC 33913 and the corresponding protein was expressed into Escherichia coli. The purified protein was able to perform both hydrolysis and synthesis of a variety of α-amino β-lactam antibiotics including (R)-ampicillin and cephalexin, with optimal ampicillin hydrolytic activity at 25 °C and pH 6.8, with kinetic parameters of kcat of 72.5 s-1 and KM of 1.1 mM. The synthesis parameters α, βo, and γ for ampicillin, determined here first for this class of proteins, are α = 0.25, βo = 42.8 M-1, and γ = 0.23, and demonstrate the excellent synthetic potential of these enzymes. An extensive study of site-directed mutations around the binding pocket of X. campestris pv. campestris AEH strongly suggests that mutation of almost any first-shell amino acid residues around the active site leads to inactive enzyme, including Y82, Y175, D207, D208, W209, Y222, and E309, in addition to those residues forming the catalytic triad, S174, H340, and D307.

Synthesis of cephalosporin-type antibiotics by coupling of their β-lactam nucleus and racemic amino acid side chains using a clathration-induced asymmetric transformation

The cephalosporin-type antibiotics Cephalexin, Cephradine and Cefadroxil have been prepared by coupling of their β-lactam nucleus and racemic amino acid side chain precursors. The initially obtained mixture of cephalosporin epimers is subjected to a clathration-induced asymmetric transformation which results in the epimerization of the epi-cephalosporin into the cephalosporin with the correct diastereomeric configuration.

Process and device for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules

The present invention provides a process for preparing liquid pharmaceutical formulations on demand from tablets and capsules.

Complexes of cephalosporins and carbacephalosporins with parabens

The invention provides complexes of the formula: STR1 wherein X is chloro, hydrogen, vinyl, or --CH3, Z is CH2 or S; n is 0-5; Y is phenyl or 1,4-cyclohexadien-1-yl; R1 and R2 are hydrogen or hydroxy, with the proviso that R1 and R2 are not both hydrogen and R3 is --COO-, --COO(C1 -C4 alkyl), --NO2 or STR2 wherein R4 is C1 -C4 alkyl.

Penicillin acylase in the industrial production of β-lactam antibiotics

Immobilized penicillin acylase is a biocatalyst suitable for the kinetically controlled industrial synthesis of semi-synthetic antibiotics in aqueous environments. Amoxiciliin and ampicillin are obtained by condensing 6-aminopenicillanic acid with the amide or ester of D-( - )-4-hydroxyphenyIglycine and D-( - )phenylglycine, respectively. Similarly, the cephalosporin antibiotics cefadroxil and cephalexin can be obtained from 7-aminodesacetoxycephalosporanic acid.

Synthesis of potential impurities of cefalexin and cefradine

The synthesis of some impurities of the cephalosporin antibiotics cefalexin and cefradine is described. These impurities which may be present in commercial samples are formed during the semi-synthetic preparation of these antibiotics or upon their degradation. The preparation of these compounds enables the validation of selective quantitative analytical methods, such as column liquid chromatography and thin layer chromatography.

Prodrug derivatives of carboxylic acid drugs

Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R1 and R2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R1 and R2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.